科研成果详情

题名Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
作者
Zhu, Hai-Dong1; Li, Hai-Liang2; Huang, Ming-Sheng3; Yang, Wei-Zhu4; Yin, Guo-Wen5; Zhong, Bin-Yan6; Sun, Jun-Hui7; Jin, Zhi-Cheng1; Chen, Jian-Jian1; Ge, Nai-Jian8; Ding, Wen-Bin9; Li, Wen-Hui10; Huang, Jin-Hua11; Mu, Wei12; Gu, Shan-Zhi13; Li, Jia-Ping14; Zhao, Hui15; Wen, Shu-Wei16; Lei, Yan-Ming17; Song, Yu-Sheng18; Yuan, Chun-Wang19; Wang, Wei-Dong20; Huang, Ming21; Zhao, Wei22; Wu, Jian-Bing23; Wang, Song24; Zhu, Xu25; Han, Jian-Jun26; Ren, Wei-Xin27; Lu, Zai-Ming28; Xing, Wen-Ge29; Fan, Yong30; Lin, Hai-Lan31; Zhang, Zi-Shu32; Xu, Guo-Hui33; Hu, Wen-Hao34; Tu, Qiang35; Su, Hong-Ying36; Zheng, Chuan-Sheng37; Chen, Yong38; Zhao, Xu-Ya39; Fang, Zhu-Ting40; Wang, Qi41; Zhao, Jin-Wei42; Xu, Ai-Bing43; Xu, Jian44; Wu, Qing-Hua45; Niu, Huan-Zhang46; Wang, Jian47; Dai, Feng48; Feng, Dui-Ping49; Li, Qing-Dong50; Shi, Rong-Shu51; Li, Jia-Rui52; Yang, Guang53; Shi, Hai-Bin54; Ji, Jian-Song55; Liu, Yu-E56; Cai, Zheng57; Yang, Po58; Zhao, Yang59; Zhu, Xiao-Li6; Lu, Li-Gong60; Teng, Gao-Jun1
发表日期2023-02-08
发表期刊Signal transduction and targeted therapy   影响因子和分区
语种英语
原始文献类型Journal Article
其他关键词OPEN-LABEL ; 1ST-LINE TREATMENT ; NEGATIVE TRIALS ; DOUBLE-BLIND ; END-POINTS ; SORAFENIB ; TACE ; COMBINATION ; BEVACIZUMAB
摘要There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world situations. In this nationwide, retrospective, cohort study, 826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT (combination group, n = 376) or TACE monotherapy (monotherapy group, n = 450) were included from January 2018 to May 2021. The primary endpoint was progression-free survival (PFS) according to modified RECIST. The secondary outcomes included overall survival (OS), objective response rate (ORR), and safety. We performed propensity score matching approaches to reduce bias between two groups. After matching, 228 pairs were included with a predominantly advanced disease population. Median PFS in combination group was 9.5 months (95% confidence interval [CI], 8.4-11.0) versus 8.0 months (95% CI, 6.6-9.5) (adjusted hazard ratio [HR], 0.70, P = 0.002). OS and ORR were also significantly higher in combination group (median OS, 19.2 [16.1-27.3] vs. 15.7 months [13.0-20.2]; adjusted HR, 0.63, P = 0.001; ORR, 60.1% vs. 32.0%; P < 0.001). Grade 3/4 adverse events were observed at a rate of 15.8% and 7.5% in combination and monotherapy groups, respectively. Our results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS, OS, and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice, with an acceptable safety profile.
资助项目National Key Research and Development Program [2018YFA0704100, 2018YFA0704104]; National Natural Science Foundation of China [81827805, 82130060]; Jiangsu Provincial Special Program of Medical Science [BE2019750]
出版者SPRINGERNATURE
ISSN2059-3635
EISSN2059-3635
卷号8期号:1
DOI10.1038/s41392-022-01235-0
页数10
WOS类目Biochemistry & Molecular Biology ; Cell Biology
WOS研究方向Biochemistry & Molecular Biology ; Cell Biology
WOS记录号WOS:000941443900001
收录类别PUBMED ; SCIE ; SCOPUS
URL查看原文
PubMed ID36750721
SCOPUSEID2-s2.0-85147640287
ESI高被引论文2023-09 ; 2023-11 ; 2024-01 ; 2024-03 ; 2024-05 ; 2024-07 ; 2024-09
通讯作者地址[Teng, Gao-Jun]Center of Interventional Radiology & Vascular Surgery,Department of Radiology,Zhongda Hospital,Medical School,Southeast University,Nanjing,210009,China ; [Zhu, Xiao-Li]Department of Interventional Radiology,The First Affiliated Hospital of Soochow University,Soochow University,Suzhou,215006,China ; [Lu, Li-Gong]Zhuhai Interventional Medical Center,Zhuhai Precision Medical Center,Zhuhai People’s Hospital,Zhuhai Hospital Affiliated with Jinan University,Jinan University,Zhuhai,519000,China
Scopus学科分类Genetics;Cancer Research
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/172628
专题附属第一医院_介入科
通讯作者Zhu, Xiao-Li; Lu, Li-Gong; Teng, Gao-Jun
作者单位
1.Center of Interventional Radiology & Vascular Surgery,Department of Radiology,Zhongda Hospital,Medical School,Southeast University,Nanjing,210009,China;
2.Department of Minimally invasive Intervention,The Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou,450008,China;
3.Department of Interventional Radiology,the Third Affiliated Hospital,Sun Yat-Sen University,Guangzhou,510630,China;
4.Department of Interventional Radiology,Union Hospital of Fujian Medical University,Fuzhou,350001,China;
5.Department of Interventional Radiology,Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing,210009,China;
6.Department of Interventional Radiology,The First Affiliated Hospital of Soochow University,Soochow University,Suzhou,215006,China;
7.Hepatobiliary and Pancreatic Interventional Treatment Center,Division of Hepatobiliary and Pancreatic Surgery,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,310003,China;
8.Department of Interventional Radiology,Eastern Hospital of Hepatobiliary Surgery,Navy Medical University (Second Military Medical University),Shanghai,200438,China;
9.Department of Interventional Radiology,Nantong First People’s Hospital,Nantong,226001,China;
10.Department of Interventional Radiology,Yancheng Third People’s Hospital,Yancheng,224008,China;
11.Department of Minimally Invasive Interventional Therapy,Sun Yat-Sen University Cancer Center,Guangzhou,510060,China;
12.Department of Vascular Surgery,Southwest Hospital,Third Military Medical University (Army Medical University),Chongqing,400038,China;
13.Department of Interventional Radiology,Hunan Cancer Hospital,Changsha,410031,China;
14.Department of Interventional Oncology,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou,510080,China;
15.Department of Interventional Radiology,The Hospital of Nantong University,Nantong,226001,China;
16.Department of Interventional Therapy,Shanxi Tumor Hospital,Taiyuan,030001,China;
17.Department of Interventional Radiology,Tibet Autonomous Region People’s Hospital,Lhasa,850000,China;
18.Department of Interventional Radiology,Ganzhou People’s Hospital,Ganzhou,341000,China;
19.Center of Interventional Oncology and Liver Diseases,Beijing Youan Hospital,Capital Medical University,Beijing,100069,China;
20.Department of Interventional Radiology,The Affiliated Wuxi People’s Hospital of Nanjing Medical University,Wuxi,214023,China;
21.Department of Minimally Invasive Interventional Therapy,Yunnan Tumor Hospital,The Third Affiliated Hospital of Kunming Medical University,Kunming,650118,China;
22.Department of Radiology,First Affiliated Hospital of Kunming Medical University,Kunming,650032,China;
23.Department of Oncology,The Second Affiliated Hospital of Nanchang University,Nanchang,330006,China;
24.Department of Interventional Radiology,Affiliated Hospital of Qingdao University,Qingdao,266000,China;
25.Department of Interventional Therapy,Peking University Cancer Hospital and Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),Beijing,100142,China;
26.Department of Interventional Radiology,Affiliated Cancer Hospital of Shandong First Medical University,Jinan,250117,China;
27.Interventional Therapy Center,The first Affiliated Hospital of Xinjiang Medical University,Urumqi,830011,China;
28.Department of Radiology,Shengjing Hospital of China Medical University,Shenyang,830011,China;
29.Department of Interventional Oncology,Tianjin Medical University Cancer Hospital,Tianjin,300060,China;
30.Department of Radiology,Tianjin Medical University General Hospital,Tianjin,300052,China;
31.Department of Tumor Interventional Therapy,Fujian Cancer Hospital,Fuzhou,350014,China;
32.Department of Radiology,The Second Xiangya Hospital,Changsha,410011,China;
33.Department of Interventional Radiology,Sichuan Cancer Hospital and Institute,Chengdu,610041,China;
34.Department of Interventional Radiology,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China;
35.Department of Hepatobiliary Oncology Surgery,Department of Interventional Oncology,Jiangxi Cancer Hospital of Nanchang University,Nanchang,330029,China;
36.Department of Interventional Radiology,The First Hospital of China Medical University,Shenyang,110001,China;
37.Department of Radiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,110001,China;
38.Department of Interventional Radiology,General hospital of Ningxia Medical University,Yinchuan,110001,China;
39.Department of Interventional Radiology,Guizhou Cancer Hospital,Guiyang,550000,China;
40.Department of Interventional Radiology,Fujian Provincial Hospital,Shengli Clinical Medical College of Fujian Medical University,Fuzhou,350001,China;
41.Department of Interventional Radiology,Third Affiliated Hospital of Soochow University,Changzhou First Hospital,Changzhou,213004,China;
42.Department of Interventional and Vascular Surgery,The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University,Changzhou,213003,China;
43.Department of Interventional Therapy,Nantong Tumor Hospital,Nantong,226006,China;
44.Department of Interventional Therapy,Jinling Hospital,School of Medicine,Nanjing University,Nanjing,210002,China;
45.Department of Interventional Radiology,Affiliated Hospital of Jiangnan University,Wuxi,214122,China;
46.Department of Interventional Radiology,The First Affiliated Hospital,and College of Clinical Medicine of Henan University of Science and Technology,Luoyang,471003,China;
47.Department of Interventional Radiology and Vascular Surgery,Peking University First Hospital,Beijing,100034,China;
48.Department of Interventional Radiology,The Second Hospital of Nanjing,Nanjing,210000,China;
49.Department of Oncology and Vascular Intervention,First Hospital of Shanxi Medical University,Taiyuan,030001,China;
50.Vascular and Interventional Department,Chongqing University Cancer Hospital,Chongqing,400000,China;
51.Department of Interventional Radiology,The Affiliated Hospital of Zunyi Medical College,Zunyi,563000,China;
52.Department of Interventional Therapy,The First Hospital of Jilin University,Changchun,130000,China;
53.Department of Radiology,The Fourth Hospital of Hebei Medical University,Shijiazhuang,China;
54.Department of Interventional Radiology,The First Affiliated Hospital of Nanjing Medical University,Nanjing,210029,China;
55.Department of Radiology,Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research,School of Medicine,Lishui Hospital of Zhejiang University,Lishui,323000,China;
56.Department of Interventional Radiology,Shanxi Provincial People’s Hospital,Taiyuan,030012,China;
57.Department of Interventional Medicine,The Second Affiliated Hospital of Zunyi Medical University,Zunyi,563000,China;
58.Department of Interventional & Vascular Surgery,The Fourth Hospital of Harbin Medical University,Harbin,150001,China;
59.Department of Biostatistics,Nanjing Medical University,Nanjing,211166,China;
60.Zhuhai Interventional Medical Center,Zhuhai Precision Medical Center,Zhuhai People’s Hospital,Zhuhai Hospital Affiliated with Jinan University,Jinan University,Zhuhai,519000,China
推荐引用方式
GB/T 7714
Zhu, Hai-Dong,Li, Hai-Liang,Huang, Ming-Sheng,et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)[J]. Signal transduction and targeted therapy,2023,8(1).
APA Zhu, Hai-Dong., Li, Hai-Liang., Huang, Ming-Sheng., Yang, Wei-Zhu., Yin, Guo-Wen., ... & Teng, Gao-Jun. (2023). Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal transduction and targeted therapy, 8(1).
MLA Zhu, Hai-Dong,et al."Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)".Signal transduction and targeted therapy 8.1(2023).

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Zhu, Hai-Dong]的文章
[Li, Hai-Liang]的文章
[Huang, Ming-Sheng]的文章
百度学术
百度学术中相似的文章
[Zhu, Hai-Dong]的文章
[Li, Hai-Liang]的文章
[Huang, Ming-Sheng]的文章
必应学术
必应学术中相似的文章
[Zhu, Hai-Dong]的文章
[Li, Hai-Liang]的文章
[Huang, Ming-Sheng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。